Outcomes Following Non-Emergent Electrical Cardioversion for Atrial Arrhythmias

© 2015 Published by Elsevier Inc. Corresponding author: Benjamin Adam Steinberg, MD, MHS; Duke Clinical Research Institute; PO Box 17969, Durham, NC 27715; Tel: 919-684-8111; Fax: 877-991-8498; benjamin.steinberg@duke.edu. Conflict of Interest Disclosures BA Steinberg: Dr. Steinberg reports funding from NIH T-32 training grant #5 T32 HL 7101-38. P Schulte: Dr. Schulte has no relevant disclosures to report. P Hofman: Dr. Hofman has no relevant disclosures to report. M Ersbøll: Dr. Ersbøll has no relevant disclosures to report. JH Alexander: Dr. Alexander reports research funding from Bristol Myers Squibb, Boehringer Ingelheim, CLS Behring, Duke Health System, National Institutes of Health, Oxygen Biotherapeutics, Perosphere, REgado Biosciences, and Vivus Pharmaceuticals (all significant); consulting, honoraria, or other services (including CME) from Portola and Regado Biosciences (modest), Duke Private Diagnostic Clinic (significant); and reimbursement for personal expenses from Bristol Myers Squibb ($5–25K). L Broderick-Forsgren: Dr. Broderick-Forsgren has no relevant disclosures to report. KJ Anstrom: Dr. Anstrom has received research support from AstraZeneca (significant), Eli Lilly & Company (significant), and Medtronic (significant); has served as a consultant for Abbott Vascular (modest), AstraZeneca (modest), Bristol-Meyers Squibb (modest), Gilead (modest), Pfizer (modest), GSK (modest), Promedior (modest), and Ikaria (modest); and has served on data monitoring committees for NIH (modest), University of North Carolina (modest), University of Miami (modest), Forest (modest), Pfizer (modest), GSK (modest), and Vertex (modest). CB Granger: Dr. Granger reports research funding from Boehringer Ingelheim, Bristol Myers Squibb, GSK, Medtronic Foundation, Merck & Co., Pfizer, Sanofi-Aventis, Takeda, The Medicines Company, Astra Zeneca, Daiichi Sankyo, Janssen Pharmaceuticals, and Bayer (all significant); consulting or other services (including CME) for Boehringer Ingelheim, Bristol Myers Squibb, GSK, HoffmanLa Roche, Sanofi-Aventis, Takeda, The Medicines Company, Astra Zeneca, Ross Medical Corporation, Janssen Pharmaceuticals, Salix Pharmaceuticals (all modest); consulting or other non-CME services for Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi-Aventis, Daiichi Sankyo (all modest), and Bristol Myers Squibb (significant). JP Piccini: Dr. Piccini reports grant funding from ARCA biopharma (>10 k), Boston Scientific (>10 k), Johnson & Johnson (>10 K), GE Healthcare (>10 k), and ResMed (>10 K); consulting for Johnson & Johnson (<10 K), Biosense Webster (<10 K), and Medtronic (<10 K). EJ Velazquez: Dr. Velazquez reports funding from Novartis (committee, honorarium; >10k); NHLBI (grants; >10k); Ikaria Pharmaceuticals (grants; >10k) BR Shah: Dr. Shah has no relevant disclosures to report.

[1]  G. Lip,et al.  Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. , 2014, International journal of cardiology.

[2]  G. Lip,et al.  CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. , 2014, Thrombosis research.

[3]  Jun Zhu,et al.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.

[4]  J. Hartikainen,et al.  Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. , 2013, Journal of the American College of Cardiology.

[5]  S. Shimizu,et al.  CHADS2 score predicts functional outcome of stroke in patients with a history of coronary artery disease , 2013, Journal of the Neurological Sciences.

[6]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[7]  G. Lip,et al.  The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. , 2013, European heart journal.

[8]  G. Lip,et al.  RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers , 2012, BMC Cardiovascular Disorders.

[9]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[10]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[11]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[12]  H. Crijns,et al.  Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. , 2006, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[13]  B. Gage,et al.  Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors , 2005, Medical care.

[14]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[15]  R. Coleman,et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.